While hypoglycemia is a predictable extension of the pharmacological effect of a secretagogue, eDKA, consistently reported in SGLT2 trials [1,30,32], is a complex metabolic complication that represents a novel clinical challenge. This evidence concerns the gene SLC5A2 and Hypoglycemia.